3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
81
Carcinoma, Non-Small-Cell Lung
73
Prostatic Neoplasms
72
Neoplasms
56
Multiple Myeloma
49
Lung Neoplasms
45
Colorectal Neoplasms
40
Melanoma
33
Neoplasm Metastasis
31
Pancreatic Neoplasms
30
Lymphoma, Non-Hodgkin
30
Leukemia, Myeloid, Acute
29
Lymphoma
28
Squamous Cell Carcinoma of Head and Neck
27
Ovarian Neoplasms
26
Carcinoma, Renal Cell
26
Leukemia, Lymphocytic, Chronic, B-Cell
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Endometrial Neoplasms
22
Stomach Neoplasms
21
Carcinoma, Hepatocellular
21
Uterine Cervical Neoplasms
20
Sarcoma
20
Glioma
20
Urinary Bladder Neoplasms
19
Recurrence
18
Rectal Neoplasms
18
Hematologic Neoplasms
18
Lymphoma, Mantle-Cell
17
Head and Neck Neoplasms
17
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Biochemically Recurrent Prostate Cancer
×
30 days
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled